StockWatch
·

MPS LTD. Q2 FY27 Results

MPSLTDQ2 FY27 Results
Filing
Result:Steady· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Raised

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue224.290.0%15.3%
Total Income226.530.3%15.2%
Expenditure157.130.1%11.9%
PBT69.400.6%0.3%
Net Profit52.103.4%6.0%
OPM34.34%3.35pp
NPM23.00%0.82pp5.18pp
EPS30.703.4%6.0%
View full financials

Revenue grew a healthy 15.4% YoY but OPM compressed ~340bps and a higher effective tax rate pulled adjusted net profit down 6%, making this an in-line quarter with margin pressure rather than a clean beat.

MPS LTD · Q2 FY27 · THE VERDICT

Margin Peak Masks Growth Timing Risk

Operating leverage thesis proved out — EBITDA margin reached 34.3%, highest on record, and the FY'27 floor was raised to ₹310 Crore. But sequential revenue was flat at 0% despite new mandate wins, concentrating all growth into a narrower H2 window. The real number to track: whether November and December actually deliver.

11 Nov 2026 · 6 min read
Revenue

₹224.3 Cr

+15.4% YoY, 0% QoQ

EBITDA Margin

34.3%

highest recent; 2nd quarter >34%

PAT

₹52.1 Cr

-6% reported (distorted by prior one-time)

Organic PAT growth

~+22%

current vs adjusted prior

The headline looks weak: profit down 6% year-over-year despite the highest operating margin in recent history. But the gap between reported and organic profit is the quarter's real story. Q2 FY'26 carried a ₹12.8 crore one-time write-back on Liberate, the clinical learning platform acquired as part of Unbound; strip that out, and organic PAT growth is roughly +22%. What the quarter actually delivered was margin — and the market saw it. The FY'27 EBITDA floor was raised from ₹300 crore to ₹310 crore, a tacit upgrade. The problem is what it masks: revenue was completely flat quarter-on-quarter, a 0% sequential, despite management claiming new large mandates in education and corporate learning were closed this quarter.

The margin thesis holds. The growth thesis doesn't—yet.

Operating leverage is the centerpiece of MPS's playbook. The Rule of 50—a venture-backed proxy for durability, calculated as growth rate plus operating margin—hit 54 in Q1 (20% growth + 34% margin). Management aspires for that to hold through the year. Q2 proves the margin half: 34.3% operating margin, the highest MPS has delivered in recent quarters, and the second time in a row above 34%. That level isn't a one-time performance; it reflects real cost discipline and scale. H1 EBITDA of ₹154 crore, if annualized at the same pace, lands at roughly ₹308–310 crore, which squares with the raised floor. So the margin upgrade is credible.

But the growth half of the Rule fell apart. Q2 revenue of ₹224.3 crore is +15.4% year-over-year, which looks healthy in isolation. But sequentially—comparing Q2 to Q1—it's a flat 0%. That's where the tension lives. Management said on the call that large education mandates (US state curriculum adoptions in Florida and California) and corporate learning contracts (healthcare workforce training via the Unbound/Liberate platform) were signed in Q2. Yet sequential revenue didn't budge. The answer, per management, is timing: these mandates have order-booked now, but won't start billing until November and December. H2, they assure, will be weighted heavily to Q4 as a result.

That's plausible on the face of it. School board cycles and healthcare procurement do run on calendars, not straight lines. But there's a secondary risk: if those Nov–Dec mandates slip even modestly—a delayed procurement sign-off, a budget-cycle hold, a customer's internal prioritization shift—Q3 will also be flat, and the full-year growth target (implied ~15% by the unchanged FY'28 guidance) could miss. The stock's market reaction has already priced in this anxiety.

Management claims vs. what holds up

Most profitable H1 in history; EBITDA grew 39% YoY

H1 revenue +17.8% YoY; Q2 margin 34.3% (highest recent). PAT -6% YoY due to ₹12.8 Cr prior one-time.

Supported

Second consecutive quarter above 34% EBITDA margin

Q2 OPM delivered 34.3%, consistent with claim. Operating leverage thesis validated.

Supported

Top 5 clients fell from 51% to 46% of revenue

Diversification improving. Client count billed rose to 839 vs. 422 prior year.

Supported

Organic research growth 22% this quarter, no acquisition

Research revenue ex-AJE grew 22%, corroborating organic momentum outside integration.

Supported

Large education and CL mandates won; will invoice Nov–Dec

Order book strong; education H1 grew 36%. Q2 revenue sequential flat. Timing is the lynchpin—not contradicted, but unproven.

Plausible, not yet realized

What changed on this call

  • FY'27 EBITDA floor raised ₹300 Cr → ₹310 Cr

  • Rule of 50 slowing: Q2 shows 0% seq. revenue vs. 54 in Q1

  • Customer diversification improving: top 5 fell from 51% to 46%

  • FY'28 guidance unchanged: ₹1,500 Cr revenue, ₹450 Cr EBITDA

  • Organic research outside AJE: 22% growth, offsetting weaker education/CL timing

  • AJE margins improving (12–13% acq. → 18% now), but organic growth soft

The bull case, the bear case, the honest read

The street's take—where the stock sits

MPS closed at ₹2,242 on November 9, down 27% from its all-time high of ₹3,079. It's below its 20-day (₹2,354) and 50-day (₹2,523) moving averages, but above its 200-day average (₹2,067). RSI is 39.2, approaching oversold but not yet there. Volume is normal, suggesting the decline is fundamental repricing, not panic.

Ownership has shifted. Foreign institutional investors (FII) trimmed from 1.47% to 1.38% quarter-over-quarter. Domestic institutional investors (DII) added, rising from 1.96% to 2.14%. Promoter stake remains locked at 68.34%. This is the classic FII-exiting-macro-anxiety / DII-accumulating-on-valuation pattern. Foreign investors are hedging India cyclical risk; domestic investors view the drawdown as an entry point.

That squares with fundamentals. Margin is undeniable; foreigners aren't exiting because unit economics deteriorated. They're exiting because the stock has run 67% off its 52-week low and growth—the justification for that multiple—is now conditional on Nov–Dec mandate realization. That's fair risk-off for a 27% drawdown. The question is whether the drawdown is buying the right pessimism.

Ranked risks—what matters most to a holder

Risks ordered by impact on the investment thesis

H2 mandate timing slips

High

If Nov–Dec education and CL billing delays, Q3 will also be flat and FY'27 growth target could miss. This is the near-term binary; market is pricing it in.

Sequential flatness signals execution or capacity constraint

High

If 0% QoQ growth persists beyond Q2, it suggests structural scaling constraint, not timing issue. Would flatten growth guidance significantly.

AJE payback extends beyond FY'28

Medium

AJE's new customer doors aren't materializing as fast as expected (organic research 22% ex-AJE implies AJE near-zero). If payback extends, FY'28 EBITDA accretion is delayed.

Customer concentration remains elevated at 46% top 5

Medium

Education and healthcare policy shifts (NIH budget cuts, school funding cycles) could materially affect demand. Healthcare nursing shortage could soften Unbound adoption if it slows.

FY'28 guidance unchanged despite raised FY'27 floor

Medium

Management raised FY'27 to ₹310 Cr but kept FY'28 at ₹1,500 Cr revenue unchanged from Q1. Signals confidence gap between near-term and medium-term.

What to watch next—three concrete tests of the thesis
  • 1 · Q3 revenue—is Nov–Dec mandate timing real or aspirational?

    If Q3 sees sequential growth inflection (>5% would be meaningful), the Nov–Dec timing narrative holds and H2 concentration is proven. If Q3 is also flat or negative, the growth thesis cracks. This is the critical near-term test.

  • 2 · AJE customer door wins and payback trajectory

    New customer solutions (pre-submission peer review, integrity mandate, author offerings) are supposed to unlock new doors by end of FY'27. The ₹70+ crore payback depends on this. Watch FY'28 guidance for evidence—if AJE is still a drag, payback extends and acquisition track record is dinged.

  • 3 · FY'28 guidance reset—does ₹1,500 Cr revenue target get adjusted?

    ₹1,500 Cr implies 40%+ CAGR from implied ₹900 Cr annualized run-rate. Aspirational if organic stays ~20%. Management will likely adjust downward or announce major acquisition. If unchanged through FY'27-end, that's a bold bet.

The verdict

MPS has proven its margin thesis: 34.3% operating margin, the highest in recent history, is no fluke. It reflects real operating leverage and discipline. The FY'27 EBITDA floor, raised to ₹310 crore, will likely hold.

But the growth thesis is now conditional. Sequential revenue flat at 0% despite mandate wins means all the year's growth is bunched into a narrower window (H2, weighted to Q4). That concentration is manageable if Nov–Dec timing holds; it's a significant miss if it doesn't. The market has already priced in this anxiety: stock down 27% from all-time high, foreign investors trimming, valuation at a discount to recent history.

Steady margin execution, but growth timing deteriorating. Not a collapse, not a growth story anymore. This is a "show-me" quarter. The number to track: H2 sequential growth. If Q3–Q4 deliver the mandated timing, the stock rebounds. If they don't, FY'28 guidance gets reset and the multiple compresses further. Margin strength alone doesn't sustain a growth multiple; MPS needs to prove growth is real, not just delayed.

Informational and educational content only. Not investment advice.